Kornimate/medical-research-clean huggingface dataset:
interventional study of wellbutrin xl in major depressive disorder with atypical features

Conditions: Depressive Disorder, Major

Summary: the aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (wellbutrin xl®) in patients with major depressive disorder (mdd) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (wellbutrin xl®) in patients with mdd with atypical features.

whether bupropion hydrochloride extended release (wellbutrin xl®) improved atypical depressive symptoms has not been investigated. the investigators assumed that bupropion hydrochloride extended release (wellbutrin xl®) will be effective and tolerable in the treatment of atypical depression in mdd patients.

Eligibility criteria:
inclusion criteria: * age over 20 years * dsm-iv episode of mdd non-psychotic with atypical features characterized by mood reactivity and 2 or more symptoms of vegetative reversal (including overeating, oversleeping, severe fatigue or leaden paralysis, and a history of rejection sensitivity) * more than 19 score on the 29-item ham-d * ability to give informed consent exclusion criteria: * bipolar depression * any axis i psychotic disorder * a history of suicide attempt, self-injurious action (excluding action with no intention of suicide) or overdosage (excluding apparently accidental overdosage) * patients with more than 3-point score of suicide (ham-d-29 item 18) or patients whose c-ssrs assessment suggests that they are or have been at significant risk for harming themselves or have actually harmed themselves, or who, in the opinion of the investigator (sub-investigator), are at significant risk for harming self or others * a history of substance abuse in the previous 12 months * a history of hypersensitivity to bupropion or any other components of the preparations used in the study (wellbutrin sr 150mg and wellbutrin xl 300 mg tablets) * serious or unstable medical disorders * starting or terminating psychotherapy during the previous 12 weeks, * ect treatment in the previous 3 months * subject has a life time diagnosis of anorexia nervosa or bulimia within the past 12 month * subject has a current or history of seizure disorder or brain injury (traumatic or disease-related) or any condition which predisposes to seizure- subject treated with other medications or treatment regimens that lower seizure threshold- subject undergoing abrupt discontinuation of alcohol or sedatives * subjects that previously failed adequate courses of pharmacotherapy from two different classes of antidepressants or previous adequate course(s) of bupropion * pregnancy or planning pregnancy - when a patient is in active reproductive age, he or she has to agree to use relevant contraception during the study * patients on monoamine oxidase inhibitors (maois) * patients being treated with any other preparations containing bupropion as the incidence of seizures is dose dependent

Keywords: bupropion hydrochloride extended release wellbutrin xl major depressive disorder with atypical features
g-csf and autologous cord blood infusion in cerebral palsy

Conditions: Cerebral Palsy

Summary: this study is performed to reveal the safety and feasibility of combination therapy with autologous cord blood mononuclear cells (cb) and g-csf as well as repeated administration of g-csf for children with cerebral palsy. the evaluation tools are as follows: (1) developmental tests (ddst, pedi, gmfm, gmfcs, macs, quest), (2) neurocognitive function test (wppsi-iv), (3) brain mri-dti, (4) peripheral blood cd34+ cell counts, (5) neurotrophic factors/anti-inflammatory cytokines.


Eligibility criteria:
inclusion criteria: * ages from 2 years to 10 years at the time of enrollment * non-severe type of cerebral palsy * willing to comply with all study procedures exclusion criteria: * previous participation within 1 year in a clinical study with stem cell therapy including cord blood, g-csf, and erythropoietin * presence of chromosomal abnormalities * unwillingness to participate clinical trial * presence of hypersensitivity reaction to g-csf * evidence of hepatic, renal, cardiac dysfunctions
power centering for seniors

Conditions: Healthy Aging; Mobility Limitation; Walking, Difficulty

Summary: walking difficulties, mobility decline and falls are prevalent among older adults. the incidence of each of these increases with age and the presence of each can negatively affect the quality of life in older adults. the purpose of this prospective clinical trial is to evaluate the efficacy of the power centering for seniors multimodal, twice weekly, 12-week group intervention program to improve the mobility and quality of life in older, community-dwelling adults.


Eligibility criteria:
inclusion criteria: * age 70 years or older * community-dwellers (i.e. not living in a skilled care or other institution) * able to walk at least 5 meters with or without a walking aid but without the assistance of another person * normal (habitual, self-paced) walking speed 80-100 cm/s * montreal cognitive assessment score 18 or more points * lnformed consent as documented by signature exclusion criteria: * clinically significant neurologic or musculoskeletal diseases which severely affect walking, e.g. advanced parkinson's disease or hemiplegia * other clinically significant non-stable medical or psychiatric conditions (e.g., renal failure, hepatic dysfunction, cardiovascular disease, advanced chronic pulmonary disease, psychosis, schizoaffective disorder, etc.) that, according to the study investigators, could endanger the participant and/or negatively affect study adherence * terminal illness * fracture (exception: teeth) in the previous 3 months * blindness * lnability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * previous participation in the power centering for seniors program * current participation in another (non-observational) clinical study

Keywords: elderly walking speed gait falls quality of life independent living gait analysis physical functional performance montral cognitive assessment multimodal exercise exercise movement techniques muscle strength postural balance tai chi qi gong
active choice in the ehr to promote statin therapy

Conditions: Cardiovascular Diseases

Summary: cardiovascular (cv) events are the leading cause of mortality in the united states. statins have been demonstrated to be an effective tool for reducing cv events and mortality, but statins are often either not prescribed or under-prescribed for patients that meet evidence-based guidelines. in this study, we will evaluate a health system initiative using active and passive choice prompts in the electronic health record to prompt cardiologists to prescribe evidence-based statin therapy. in partnership with the health system, this will be conducted as a randomized, controlled trial to evaluate its effect.

this study will use a randomized, controlled trial to evaluate a health system initiative. cardiologists randomly assigned to the control arm will receive no interventions. for cardiologists randomly assigned to the active choice intervention, the electronic health record will be used to prompt cardiologists to initiate or change statin therapy for patients not on evidenced-based guidelines based on the 2013 american college of cardiology / american heart association (acc/aha) and the national lipid association (nla) through a "best practice alert" in epic which appears on the screen and forces a decision before the clinician can move on. for cardiologists randomly assigned to the passive choice intervention, the electronic health record will be used to create a passive alert using the same evidence-based guidelines. the passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision. the intervention period will be 6 months in duration.

Eligibility criteria:
inclusion criteria: * have a cardiologist at the university of pennsylvania health system * meets 2013 acc/aha or nla guidelines for statin prescription exclusion criteria: * allergy to statins * severe renal insufficiency defined as glomerular filtration rate (gfr) less than 30 ml/min or on dialysis * adverse reaction to statins including a) myopathy, b)rhabdomyolysis, c)hepatitis * pregnant * on a pcsk9 inhibitor medication
relationship of vasoactive peptide levels to portal pressure and patient outcomes in patients with hepatic cirrhosis

Conditions: Portal Hypertension

Summary: investigate vasoactive medicators in portal hypertension on stored sera


Eligibility criteria:
inclusion criteria: * portal hypertension exclusion criteria: * nil
parkinson's disease treatment with coenzyme q10

Conditions: Parkinson's Disease

Summary: the purpose of this study is to compare the effects of varying dosage of coenzyme q10 (coq10) versus a placebo in the treatment of parkinson's disease (pd) in patients with early, untreated pd.

four groups of 20 subjects/group of subjects will be randomly assigned to receive coq10 (at doses of 300, 600 or 1200 mg/day) or matching placebo. a subject must have early pd that does not require treatment. a subject will be evaluated at a screening visit, a baseline visit (after which the subject begins to take the study drug) and visits at 1, 4, 8, 12, and 16 months after the baseline visit. the subject will be followed until she/he needs treatment with levodopa or for a maximum of 16 months. because coq10 is a component of the mitochondria (the part of a cell that makes energy), blood samples will be taken at the baseline visit and the last visit to study mitochondrial function.

Eligibility criteria:
inclusion criteria: * the subjects must have the three cardinal features of pd: slowness of movement, resting tremor and rigidity. the signs of pd must be greater on one side. exclusion criteria: * disorders that mimic pd. * other serious medical problems.

Keywords: parkinson's disease coenzyme q10
a study of the tumor microenvironment affecting the efficacy of immunotherapy for esophageal cancer

Conditions: Esophageal Cancer

Summary: this study is a retrospective study of clinical specimens. the study subjects were patients with esophageal cancer who received immunotherapy. tumor tissue specimens surgically removed from patients before treatment will be collected primarily. in situ immunohistochemistry and multicolor immunofluorescence will be performed. we hypothesize that there are differences in lipid metabolism-related proteins in tumor tissues and immune cells in the preexisting tumor microenvironment in patients with esophageal cancer prior to immunotherapy, and that there is a link between such differences and the efficacy of immunotherapy.


Eligibility criteria:
inclusion criteria: 1. esophageal cancer patients receiving immunotherapy 2. radical esophagectomy for esophageal cancer at our institution prior to receiving immunotherapy 3. age greater than or equal to 18 years and less than or equal to 75 years old imaging to assess patient efficacy after cycle 2 immunotherapy (cr/pr, sd/pd according to recist 1.1) 4. pathology tumor tissue available exclusion criteria: 1. clinical and pathologic information not available 2. combined history of other malignant tumors 3. unavailability of surgically resected tissue 4. preoperative neoadjuvant therapy 5. radical esophagectomy for esophageal cancer not performed prior to immunotherapy
emr versus csp in the treatment of sessile serrated lesions less than 10mm in size

Conditions: Colorectal Sessile Serrated Lesion

Summary: a prospective, single-center, open-label, randomized controlled study to compare the effectiveness and safety of endoscopic mucosal resection (emr) and cold snare polypectomy (csp) in treating colorectal sessile serrated lesions (ssls) less than 10mm in size.

1. patients are undergone screening, surveillance, or therapeutic colonoscopy at the endoscopy department of gastrointestinal endoscopy center of huadong hospital affiliated to fudan university. 2. randomize patients with suspicious sessile serrated lesions (ssls) less than 10mm in size into 2 interventional groups based on random function of statistical package for the social sciences (spss) 20.0, including (1) group 1: endoscopic mucosal resection (emr) and (2) group 2: cold snare polypectomy (csp). 3. collecting variables which consist of primary and secodary outcomes.

Eligibility criteria:
inclusion criteria: * aged between 35 and 75 years * suspected sessile serrated lesions less than 10mm in size in screening, surveillance or therapeutic colonoscopy * 0-is or 0-iia according to paris classification * type 1 according to nice and jnet classification * type ii according to pit pattern * patients must sign an informed consent form prior to registration in study exclusion criteria: * unsuitable for removal by emr or csp * suspected dysplasia or malignancy * recurrent sessile serrated lesions after endoscopic resection * familial adenomatous polyposis, lynch syndrome or serrated polyposis syndrome * history of inflammatory bowel disease * patients taking anticoagulant and antiplatelet agents before the examination * severe illness or other high-risk conditions that prevent the patient from cooperating with or tolerating endoscopic therapy * refusal to sign the informed consent form or any other factors that are not suitable for enrollment or affect the ability to participate in the study

Keywords: sessile serrated lesion cold snare polypectomy endoscopic mucosal resection
effectiveness and safety of nexpowder as an endoscopic hemostatic treatment

Conditions: GastroIntestinal Bleeding

Summary: in patients who show signs of bleeding and bleeding after polypectomy such as emr and esd for polyps with a diameter of 2 cm or more in the lower gastrointestinal tract, the effectiveness and safety of nexpowder as an endoscopic hemostatic treatment are confirmed.

total number of target subjects 66 test group 33 / control group: 33 if endoscopic polypectomy is performed on polyps of 2cm or more, the probability of bleeding as a complication is 6.5%. this clinical study is an observational study to confirm the safety and effectiveness of nexpowder, an endoscopic hemostatic powder after colonoscopy polypectomy, and an exploratory evaluation of 60 patients is conducted.

Eligibility criteria:
inclusion criteria: 1. adult volunteers aged 19 or older during screening 2. a person who is scheduled to perform polypectomy for polyps with a diameter of 2 cm or more, such as endoscopic mucosal resection (emr) or endoscopic submucosal dissection (esd) 3. if the researcher agrees to voluntarily participate in the clinical study and determines that the subject cannot voluntarily consent due to the elderly aged 80 or older or other emergency situations, a written consent of the subject's legal representative is required exclusion criteria: 1. upper gastrointestinal bleeding 2. if ulcerative bleeding is not caused by the procedure 3. if you are suffering from a blood clotting disorder 4. aspirin and anticoagulant medications cannot be discontinued 5. pregnant or lactating 6. where colonoscopy is prohibited due to comorbid diseases, etc 7. if the bleeding area cannot be identified or the bleeding area cannot be reached with an endoscope 8. if you have participated in a relevant clinical trial that may affect the results of this study within the last one month 9. those with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose galactose malabsorption 10. a person who is hypersensitive to food additive blue no. 1 or has a history of allergies 11. in the case where the researcher determines that it is inappropriate to participate in clinical trials due to other reasons other than the above selection exclusion criteria
fungal infection after oral cavity surgeries

Conditions: Prevalence of Fungal Infection in Patients Undergoing Oral Cavity Surgery Without Treatment With Antifungal Drug

Summary: this prospective study we will examine the prevalence of fungal infection in patients undergoing oral cavity surgery without treatment with antifungal drug


Eligibility criteria:
inclusion criteria: * age over 18 exclusion criteria: * previous oral cavity surgery. * previous radiotherapy to the head and neck. * previous treatment with antifungal drugs in the 30 days preceding the surgery immunocompomised state at the date of surgery. * pregnancy * lack of follow-up
platelet rich plasma as a treatment for resistant corneal ulcers

Conditions: Cornea Ulcer

Summary: this prospective study involved 14 patients aged \> 18 years with rcus not responding to conventional treatment. all patients were treated with e-prp drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin a once daily for one month. all patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. in each visit, the following parameters were assessed: best corrected visual acuity (bcva), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

the present prospective study involved 14 patients aged \> 18 years with rcus not responding to conventional treatment. all patients were treated with e-prp drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin a once daily for one month. all patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. in each visit, the following parameters were assessed: best corrected visual acuity (bcva), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

Eligibility criteria:
inclusion criteria: * resistant corneal ulcers exclusion criteria: * history of topical anesthetic abuse, diagnosed with corneal dystrophies, history of neurotrophic corneal ulcers or chemical burn ulcer. other exclusion criteria were pregnancy of systemic diseases or therapies affecting platelets count e.g. aspirin.
intralase vs hansatome flaps in lasik

Conditions: Myopia

Summary: this study compared the clinical outcomes between fellow eyes randomized to either intralase femtosecond laser-created flaps or hansatome mechanical keratome-created flaps during wavefront-guided laser in situ keratomileusis.


Eligibility criteria:
inclusion criteria: inclusion criteria were "t 6.00 d of spherical myopia, "t 3.00 d of refractive astigmatism, stable refraction (less than 0.50d per year of sphere or cylinder), corneal diameter less than 11.0 mm to allow for suction fixation ring, soft contact wearer with discontinuation of wear at least 7 days prior to preoperative evaluation, visual acuity correctable to at least 20/20 in both eyes, more than 21 years of age, ability to participate in follow-up examinations for 12 months after lasik surgery. in order to fairly compare the visual outcomes of the two keratomes, patients were required to have closely matched eyes, in terms of refractive error. exclusion criteria:exclusion criteria include rigid gas permeable contact lens wearer, severe dry eyes, severe blepharitis, anterior segment pathology (cataracts or corneal scarring or neovascularization within 1 mm of intended ablation zone), recurrent corneal erosion, severe basement membrane disease, progressive or unstable myopia or keratoconus, unstable corneal mires on central keratometry, corneal thickness in which lasik procedure would result in less than 250 micros or remaining posterior corneal thickness below the flap postoperatively, baseline standard manifest refraction \> 0.75 d more minus in sphere power, or a difference of greater than 0.50d in cylinder power compared to baseline standard cycloplegic refraction, two eyes for which the baseline standard cycloplegic refraction differ from each other more than 0.75 in sphere, 0.50 d in cylinder, or have a different type of astigmatism (i.e. with-the-rule) when the cylinder is \> 0.50d, or preoperative assessment of ocular topography and/or aberrations indicates that either eye is not suitable candidate for lasik vision correction procedure (ie forme fruste keratoconus, corneal warpage, or pellucid marginal degeneration), previous intraocular or corneal surgery, and history of herpes zoster or simplex keratitis, patients on systemic corticosteroid or immunosuppressive therapy, immunocompromised subjects or clinically significant atopic disease, connective tissue disease, or diabetes, steroid responder, macular pathology, pregnant or lactating patients, patients with sensitivity to planned study concomitant medications or patients participating in another ophthalmic drug or device clinical trial.
the effect of a custom pillow on sleep quality in patients with nonoperative rotator cuff syndrome

Conditions: Rotator Cuff Injuries

Summary: the objective of this study is to determine if a pillow sleep aid improves sleep quality in the short term for patients who have shoulder pain from a rotator cuff injury and are being managed non-operatively.

patients who have shoulder pain from a rotator cuff injury will be identified in the outpatient clinic and offered the chance to enroll in the study. informed consent will be obtained. there will be two groups of patients in this study; those that receive the pillow sleep aid (the intervention group) and those that do not (the control group). the pillow sleep aid that will be investigated in this project is the "medcline shoulder relief system," a product of amenity health inc.. the pillow will be delivered to the intervention group at no cost. patients in both groups will be prescribed the same physical therapy protocols. at the end of the trial period, patients in the control group will be offered the option to receive a pillow. those that accept will be surveyed at similar intervals as the original intervention group.

Eligibility criteria:
inclusion criteria: * age \>18 and a diagnosis of rotator cuff syndrome which is being treated non-operatively. exclusion criteria: * history of prior shoulder surgery, receiving a corticosteroid injection at initial visit, lack of mailing address, non-english speaking patient, inability to sleep on one's side, preexisting clinical insomnia and obstructive sleep apnea.